ALPHA–SYNUCLEIN IMAGING PRIZE

Funding Agency:
Michael J. Fox Foundation for Parkinson's Research

The Michael J. Fox Foundation is sponsoring a $2 million prize to the first team to develop a viable selective alpha–synuclein PET tracer and agree to make that tracer available broadly.

The ability to image alpha-synuclein deposition in the brain would be a game-changing achievement for the Parkinson's disease (PD) field. The accumulation of aggregated alpha-synuclein is a pathological hallmark of PD and a priority target for drug development given its hypothesized contribution to neurodegeneration. In vivo imaging of alpha-synuclein pathology could be useful as a biomarker of the presence of disease and disease progression and as a pharmacodynamic tool for drug development. With this prize, the Foundation seeks to attract research teams and accelerate momentum to speed the development of such a tracer.

Deadline: There is no deadline for submissions. The $2 million award will be issued to the first contestant who submits compelling evidence of a viable selective tracer and agrees to its widespread use. If no award is given by mid-2018, The Michael J. Fox Foundation will evaluate the state of the field and utility of such a prize.

Agency Website

Amount

$2,000,000

Funding Type

Grant

Eligibility

Faculty
Junior Faculty

Category

Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational